Leukemia Research
Volume 26, Issue 3 , Pages 241-248 , March 2002

High serum soluble CD44 is correlated with a poor outcome of aggressive non-Hodgkin's lymphoma

  • Nozomi Niitsu

      Affiliations

    • Department of Hematology and Internal Medicine, Internal Medicin IV, Kitasato University School of Medicine, 1-15-1 Kitasato, Sagamihara-Shi, Kanagawa 228-8555, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81-42-778-8811; Fax: +81-42-778-9847
    • ,
  • Kimiko Iijima

      Affiliations

    • First Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan

Received 20 February 2001 ,Accepted 25 June 2001.

References 

  1. Shipp MA. A predictive model for aggressive NHL. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N. Engl. J. Med. 1993;329:987–994
  2. Stamenkovic I, Amiot M, Pesando JM, Seed B. A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family. Cell. 1989;56:1057–1062
  3. Picker LJ, Nakache M, Butcher EC. Monoclonal antibodies to human lymphocyte horming receptors define a novel class of adhesion molecules in diverse cell types. J. Cell. Biol. 1989;109:927–937
  4. Wielenga VJ, Heider KH, Offerhaus GJ, Adolf GR, van den Berg FM, Ponta H, et al. Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res. 1993;53:4754–4756
  5. Gunthert U, Hofmann M, Rudy W, Reber S, Zoller M, Haussmann I, et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell. 1991;65:13–24
  6. Taylor DD, Gercel-Taylor C, Gall SA. Expression and shedding of CD44 variant isoforms in paitients with gynecologic malignancies. J. Soc. Gynecol. Invest. 1996;3:289–294
  7. Guo YJ, Liu G, Wang X, Jin D, Wu M, Ma J, et al. Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer. Cancer Res. 1994;54:422–426
  8. Kan M, Kanayama H, Naruo S, Tsuji M, Kojima K, Kurokawa Y, et al. Serological evaluation of soluble CD44 in renal cancer. Jpn. J. Cancer Res. 1996;87:1191–1194
  9. De Rossi G, Marroni P, Paganuzzi M, Mauro FR, Tenca C, Zarcone D, et al. Increased serum levels of soluble CD44 standard, but not of variant isoforms v5 and v6, in B cell chronic lymphocytic leukemia. Leukemia. 1997;11:134–141
  10. Nasu H, Hibi N, Ohyashiki JH, Hara A, Kubono K, Tsukada Y, et al. Serum soluble CD44 levels for monitoring disease states in acute leukemia and myelodysplastic syndromes. Int. J. Oncol. 1998;13:525–530
  11. Ristamaki R, Joensuu H, Salmi M, Jalkanen S. Serum CD44 in malignant lymphoma: an association with treatment response. Blood. 1994;84:238–243
  12. Hiddeman W, Longo DL, Coiffier B, Fisher RI, Cabanillas F, Cavalli F, et al. Lymphoma classification — the gap between biology and clinical management is closing. Blood. 1996;88:4085–4089
  13. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the committee on Hodgkin's disease staging classification. Cancer Res. 1971;3:1860–1861
  14. Niitsu N, Umeda M. Biweekly COP-BLAM (cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin and procarbazine) regimen combined with granulocyte colony stimulating factor (G-CSF) for intermediate-grade non-Hodgkin's lymphoma. Eur. J. Haematol. 1996;56:163–167
  15. Niitsu N, Umeda M. COP-BLAM regimen combined with granulocyte colony-stimulating factor (G-CSF) and high-grade non-Hodgkin's lymphoma. Eur. J. Haematol. 1995;55:88–92
  16. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. WHO, Geneva, Switzerland, 1979.
  17. Wilcoxon F. Individual comparisons by ranking methods. Biometrics Bull. 1945;1:80–83
  18. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep. 1966;50:163–170
  19. Cox DR. Regression models and life tables. J. Stat. Soc. Br. 1972;34:187–202
  20. Underhill C. CD44: the hyaluronan receptor. J. Cell. Sci. 1992;103:293–298
  21. Lesley J, Hyman R, Kincade PW. CD44 and its interaction with the extracellular matrix. Adv. Immunol. 1993;54:271–335
  22. Screaton GR, Bell MV, Jackson DG, Cornelis RB, Gerth U, Bell JI:. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc. Natl. Acad. Sci. USA. 1992;89:12160–12164
  23. Naor D. CD44: structure, function, and association with the malignant process. Adv. Cancer Res. 1997;71:241–319
  24. Pals ST, Horst E, Ossekoppele GJ, Figdor CG, Scheper RJ, Meijer CJLM. Expresion of lymphocyte horming receptor as a mechanism of dissemination in non-Hodgkin's lymphoma. Blood. 1989;73:885–888
  25. Koopman G, Heider K-H, Horst E, Adolf GR, van Den Berg F, Ponta H, et al. Actived human lymphocytes and aggressive non-Hodgkin's lymphomas express a homologue of the rat metastasis-associated variant of CD44. J. Exp. Med. 1993;177:897–904
  26. Legras S, Gunthert U, Stauder R, Curt F, Oliferenko S, Kluin-Nelemans HC, et al. A strong expression of CD44-v6 correlates with shorter survival of patients with acute myeloid leukemia. Blood. 1998;91:3401–3413
  27. Saito H, Tsujitani S, Katano K, Ikeguchi M, Maeta M, Kaibara N. Serum concentration of CD44 variant 6 and its relation to prognosis in patients with gastric carcinoma. Cancer. 1998;83:1094–1101
  28. Guo YJ, Liu G, Wang X, Jin D, Wu M, Ma J, et al. Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer. Cancer Res. 1994;54:422–426
  29. Ristamaki R, Joensuu H, Hagberg H, Kalkner KM, Jalkanen S. Clinical significance of circulating CD44 in non-Hodgkin's lymphoma. Int. J. Cancer. 1998;79:221–225
  30. Ichikawa A, Kinoshita T, Watanabe T, Kato H, Nagai H, Tsushita K, et al. Mutations of the p53 gene as a prognostic facotr in aggressive B-cell lymphoma. N. Engl. J. Med. 1997;337:529–534
  31. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–511
  32. Niitsu N, Sasaki K, Umeda M. A high serum soluble Fas/APO-1 level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma. Leukemia. 1999;13:1434–1440
  33. Niitsu N, Okabe-Kado J, Kasukabe T, Yamamoto-Yamaguchi Y, Umeda M, Honma Y. Prognostic implications of the differentiation inhibitory factor nm23-H1 protein in the plasma of aggressive non-Hodgkin's lymphoma. Blood. 1999;94:3541–3550
  34. Sasaki K, Niitsu N. Elevated serum levels of soluble CD44 variant 6 are correlated with shorter survival in aggressive non-Hodgkin's lymphoma. Eur. J. Haematol. 2000;65:195–202

PII: S0145-2126(01)00122-9

Leukemia Research
Volume 26, Issue 3 , Pages 241-248 , March 2002

Article Tools

* Image Usage & Resolution